Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies

References

• Wong P, Pamer EG. CD8 T cell responses to infectious pathogens. Annu Rev Immunol. 2003;21:29–13. doi:10.1146/annurev.immunol.21.120601.141114.
   PubMed Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020 May 20;1–18. doi:10.1038/s41577-020-0306-5.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy A, Jimeno A. Bispecific antibodies for cancer therapy: A review. Pharmacol Ther. 2018;185:122–134. doi:10.1016/j.pharmthera.2017.12.002.
   PubMed Web of Science ®Google Scholar
• June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Sci. 2018;359(6382):1361–1365. doi:10.1126/science.aar6711.
   PubMed Web of Science ®Google Scholar
• Neefjes J, Jongsma MLM, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 2011;11(12):823–836. doi:10.1038/nri3084.
   PubMed Web of Science ®Google Scholar
• Embgenbroich M, Burgdorf S. Current concepts of antigen cross-presentation. Front Immunol. 2018;9(JUL):1643. doi:10.3389/fimmu.2018.01643.
   PubMed Web of Science ®Google Scholar
• Boegel S, Löwer M, Bukur T, Sorn P, Castle JC, Sahin U. HLA and proteasome expression body map. BMC Med Genomics. 2018;11(1):36. doi:10.1186/s12920-018-0354-x.
   PubMed Web of Science ®Google Scholar
• Fisher JPH, Heuijerjans J, Yan M, Gustafsson K, Anderson J. γδ T cells for cancer immunotherapy: A systematic review of clinical trials. OncoImmunol. 2014;3(1):e27572. doi:10.4161/onci.27572.
   PubMed Web of Science ®Google Scholar
• Daley SR, Teh C, Hu DY, Strasser A, Gray DHD. Cell death and thymic tolerance. Immunol Rev. 2017;277(1):9–20. doi:10.1111/imr.12532.
   PubMed Web of Science ®Google Scholar
• Sebzda E, Mariathasan S, Ohteki T, Jones R, Bachmann MF, Ohashi PS. Selection of the T cell repertoire. Annu Rev Immunol. 1999;17(1):829–874. doi:10.1146/annurev.immunol.17.1.829.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immun. 1999;10(3):281–287. doi:10.1016/S1074-7613(00)80028-X.
   Web of Science ®Google Scholar
• Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nat Rev Cancer. 2012;12(4):307–313. doi:10.1038/nrc3246.
   PubMed Web of Science ®Google Scholar
• Coulie PG, van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135–146. doi:10.1038/nrc3670.
   PubMed Web of Science ®Google Scholar
• Leko V, Rosenberg SA. Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors. Cancer Cell. 2020 Aug. doi:10.1016/j.ccell.2020.07.013.
   PubMed Web of Science ®Google Scholar
• Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005;102(44):16013–16018. doi:10.1073/pnas.0500090102.
   PubMed Web of Science ®Google Scholar
• Garcia-Garijo A, Fajardo CA, Gros A. Determinants for neoantigen identification. Front Immunol. 2019;10:1392. doi:10.3389/fimmu.2019.01392.
   PubMed Web of Science ®Google Scholar
• Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C. Translational implications of tumor heterogeneity. Clin Cancer Res. 2015;21(6):1258–1266. doi:10.1158/1078-0432.ccr-14-1429.
   PubMed Web of Science ®Google Scholar
• Joshi K, Robert de Massy M, Ismail M, Reading JL, Uddin I, Woolston A, Hatipoglu E, Oakes T, Rosenthal R, Peacock T, et al. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nat Med. 2019;25(10):1549–1559. doi:10.1038/s41591-019-0592-2.
   PubMed Web of Science ®Google Scholar
• Jia Q, Chiu L, Wu S, Bai J, Peng L, Zheng L, Zang R, Li X, Yuan B, Gao Y, et al. Tracking neoantigens by personalized circulating tumor DNA sequencing during checkpoint blockade immunotherapy in non‐small cell lung cancer. Adv Sci. 2020;7(9):1903410. doi:10.1002/advs.201903410.
   Web of Science ®Google Scholar
• Peters B, Nielsen M, Sette A. T cell epitope predictions. Annu Rev Immunol. 2020;38(1):123–145. doi:10.1146/annurev-immunol-082119-124838.
   PubMed Web of Science ®Google Scholar
• Bulik-Sullivan B, Busby J, Palmer CD, Davis MJ, Murphy T, Clark A, Busby M, Duke F, Yang A, Young L, et al. Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nat Biotechnol. 2019;37(1). doi:10.1038/nbt.4313.
   Web of Science ®Google Scholar
• Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KCF, Campbell KM, Lamb A, Ward JP, Sidney J, Blazquez AB, et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell. 2020;183(3):818–834.e13. doi:10.1016/j.cell.2020.09.015.
   PubMed Web of Science ®Google Scholar
• Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nat. 2014;515(7528):572–576. doi:10.1038/nature14001.
   Web of Science ®Google Scholar
• Bassani-Sternberg M, Bräunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, Straub M, Weber J, Slotta-Huspenina J, Specht K, et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun. 2016;7(1):13404. doi:10.1038/ncomms13404.
   PubMed Web of Science ®Google Scholar
• Haen SP, Löffler MW, Rammensee HG, Brossart P. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat Rev Clin Oncol. 2020 Jun 22;1–16. doi:10.1038/s41571-020-0387-x.
   PubMed Web of Science ®Google Scholar
• Joglekar AV, Leonard MT, Jeppson JD, Swift M, Li G, Wong S, Peng S, Zaretsky JM, Heath JR, Ribas A, et al. T cell antigen discovery via signaling and antigen-presenting bifunctional receptors. Nat Methods. 2019;16(2):191–198. doi:10.1038/s41592-018-0304-8.
   PubMed Web of Science ®Google Scholar
• Kisielow J, Obermair FJ, Kopf M. Deciphering CD4+ T cell specificity using novel MHC–TCR chimeric receptors. Nat Immunol. 2019;20(5):652–662. doi:10.1038/s41590-019-0335-z.
   PubMed Web of Science ®Google Scholar
• Joly E, Hudrisier D. What is trogocytosis and what is its purpose? Nat Immunol. 2003;4(9):815. doi:10.1038/ni0903-815.
   PubMed Web of Science ®Google Scholar
• Li G, Bethune MT, Wong S, Joglekar AV, Leonard MT, Wang JK, Kim JT, Cheng D, Peng S, Zaretsky JM, et al. T cell antigen discovery via trogocytosis. Nat Methods. 2019;16(2):183–190. doi:10.1038/s41592-018-0305-7.
   PubMed Web of Science ®Google Scholar
• Kula T, Dezfulian MH, Wang CI, Abdelfattah NS, Hartman ZC, Wucherpfennig KW, Lyerly HK, Elledge SJ. T-scan: a genome-wide method for the systematic discovery of T cell epitopes. Cell. 2019;178(4):1016–1028.e13. doi:10.1016/j.cell.2019.07.009.
   PubMed Web of Science ®Google Scholar
• Sharma G, Rive CM, Holt RA. Rapid selection and identification of functional CD8+ T cell epitopes from large peptide-coding libraries. Nat Commun. 2019;10(1):1–13. doi:10.1038/s41467-019-12444-7.
   PubMed Web of Science ®Google Scholar
• Gee MH, Han A, Lofgren SM, Beausang JF, Mendoza JL, Birnbaum ME, Bethune MT, Fischer S, Yang X, Gomez-Eerland R, et al. Antigen identification for orphan T cell receptors expressed on tumor-infiltrating lymphocytes. Cell. 2018;172(3):549–563.e16. doi:10.1016/j.cell.2017.11.043.
   PubMed Web of Science ®Google Scholar
• Ettinghausen SE, Rosenberg SA. The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. Springer Semin Immunopathol. 1986;9(1):51–71. doi:10.1007/BF00201905.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and Interleukin 2. JNCI. 1994;86(15):1159–1166. doi:10.1093/jnci/86.15.1159.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Clinical immunotherapy studies in the surgery branch of the U.S. National Cancer Institute: brief review. Cancer Treat Rev. 1989;16(SUPPL. A):115–121. doi:10.1016/0305-7372(89)90031-5.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Sci. 2002;298(5594):850–854. doi:10.1126/science.1076514.
   PubMed Web of Science ®Google Scholar
• Sackstein R, Schatton T, Barthel SR. T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. Lab Invest. 2017;97(6):669–697. doi:10.1038/labinvest.2017.25.
   PubMed Web of Science ®Google Scholar
• Simoni Y, Becht E, Fehlings M, Loh CY, Koo S-L, Teng KWW, Yeong JPS, Nahar R, Zhang T, Kared H, et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nat. 2018;557(7706):575–579. doi:10.1038/s41586-018-0130-2.
   Web of Science ®Google Scholar
• Scheper W, Kelderman S, Fanchi LF, Linnemann C, Bendle G, de Rooij MAJ, Hirt C, Mezzadra R, Slagter M, Dijkstra K, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med. 2019;25(1):89–94. doi:10.1038/s41591-018-0266-5.
   PubMed Web of Science ®Google Scholar
• Pasetto A, Gros A, Robbins PF, Deniger DC, Prickett TD, Matus-Nicodemos R, Douek DC, Howie B, Robins H, Parkhurst MR, et al. Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor. Cancer Immunol Res. 2016;4(9):734–743. doi:10.1158/2326-6066.CIR-16-0001.
   PubMed Web of Science ®Google Scholar
• Lu Y-C, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res. 2014;20(13):3401–3410. doi:10.1158/1078-0432.ccr-14-0433.
   PubMed Web of Science ®Google Scholar
• Lu Y-C, Yao X, Li YF, El-Gamil M, Dudley ME, Yang JC, Almeida JR, Douek DC, Samuels Y, Rosenberg SA, et al. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol. 2013;190(12):6034–6042. doi:10.4049/jimmunol.1202830.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Lu Y-C, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19(6):747–752. doi:10.1038/nm.3161.
   PubMed Web of Science ®Google Scholar
• Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Sci. 2015;350(6266):1387–1390. doi:10.1126/science.aad1253.
   PubMed Web of Science ®Google Scholar
• Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Sci. 2014;344(6184):641–645. doi:10.1126/science.1251102.
   PubMed Web of Science ®Google Scholar
• Assadipour Y, Zacharakis N, Crystal JS, Prickett TD, Gartner JJ, Somerville RPT, Xu H, Black MA, Jia L, Chinnasamy H, et al. Characterization of an immunogenic mutation in a patient with metastatic triple-negative breast cancer. Clin Cancer Res. 2017;23(15):4347–4353. doi:10.1158/1078-0432.CCR-16-1423.
   PubMed Web of Science ®Google Scholar
• Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24(6):724–730. doi:10.1038/s41591-018-0040-8.
   PubMed Web of Science ®Google Scholar
• Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, et al. Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. J ImmunoTher Cancer. 2019;7(1):40. doi:10.1186/s40425-018-0492-x.
   PubMed Web of Science ®Google Scholar
• Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Sci. 2017;356(6334):200–205. doi:10.1126/science.aak9510.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Sci. 2016;351(6280):1463–1469. doi:10.1126/science.aaf1490.
   PubMed Web of Science ®Google Scholar
• Wong YNS, Joshi K, Khetrapal P, Ismail M, Reading JL, Sunderland MW, Georgiou A, Furness AJS, Aissa AB, Ghorani E, et al. Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. J Exp Med. 2018;215(11):2748–2759. doi:10.1084/jem.20181003.
   PubMed Web of Science ®Google Scholar
• Jang M, Yew PY, Hasegawa K, Ikeda Y, Fujiwara K, Fleming GF, Nakamura Y, Park JH. Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing. OncoImmunol. 2015;4(11):e1030561. doi:10.1080/2162402X.2015.1030561.
   PubMedGoogle Scholar
• Inozume T, Hanada K, Wang QJ, Ahmadzadeh M, Wunderlich JR, Rosenberg SA, Yang JC. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother. 2010;33(9):956–964. doi:10.1097/CJI.0b013e3181fad2b0.
   PubMed Web of Science ®Google Scholar
• Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016;22(4):433–438. doi:10.1038/nm.4051.
   PubMed Web of Science ®Google Scholar
• Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246–2259. doi:10.1172/JCI73639.
   PubMed Web of Science ®Google Scholar
• Fernandez-Poma SM, Salas-Benito D, Lozano T, Casares N, Riezu-Boj JI, Mancheño U, Elizalde E, Alignani D, Zubeldia N, Otano I, et al. Expansion of tumor-infiltrating CD8+ T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy. Cancer Res. 2017;77(13):3672–3684. doi:10.1158/0008-5472.CAN-17-0236.
   PubMed Web of Science ®Google Scholar
• Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, Greenberg PD. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood. 2007;110(1):201–210. doi:10.1182/blood-2006-11-056168.
   PubMed Web of Science ®Google Scholar
• Parkhurst M, Gros A, Pasetto A, Prickett T, Crystal JS, Robbins P, Rosenberg SA. Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression. Clinical Cancer Research. 2017. doi:10.1158/1078-0432.CCR-16-2680.
   Google Scholar
• Cafri G, Yossef R, Pasetto A, Deniger DC, Lu Y-C, Parkhurst M, Gartner JJ, Jia L, Ray S, Ngo LT, et al. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. Nat Commun. 2019;10(1):449. doi:10.1038/s41467-019-08304-z.
   PubMed Web of Science ®Google Scholar
• Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, Goodall CP, Blair TC, Fox BA, McDermott JE, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018;9(1):2724. doi:10.1038/s41467-018-05072-0.
   PubMed Web of Science ®Google Scholar
• van der Leun AM, Thommen DS, Schumacher TN. CD8+ T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20(4):218–232. doi:10.1038/s41568-019-0235-4.
   PubMed Web of Science ®Google Scholar
• Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Sci. 1996;274(5284):94–96. doi:10.1126/science.274.5284.94.
   PubMed Web of Science ®Google Scholar
• Bentzen AK, Hadrup SR. Evolution of MHC-based technologies used for detection of antigen-responsive T cells. Cancer Immunol ImmunoTher. 2017;66(5):657–666. doi:10.1007/s00262-017-1971-5.
   PubMed Web of Science ®Google Scholar
• Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ, van de Kasteele W, Rimmelzwaan GF, Haanen JBAG, Ovaa H, et al. Design and use of conditional MHC class I ligands. Nat Med. 2006;12(2):246–251. doi:10.1038/nm1360.
   PubMed Web of Science ®Google Scholar
• Rodenko B, Toebes M, Hadrup SR, van Esch WJE, Molenaar AM, Schumacher TNM, Ovaa H. Generation of peptide–MHC class I complexes through UV-mediated ligand exchange. Nat Protoc. 2006;1(3):1120–1132. doi:10.1038/nprot.2006.121.
   PubMed Web of Science ®Google Scholar
• Saini SK, Tamhane T, Anjanappa R, Saikia A, Ramskov S, Donia M, Svane IM, Jakobsen SN, Garcia-Alai M, Zacharias M, et al. Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells. Sci Immunol. 2019;4(37):9039. doi:10.1126/sciimmunol.aau9039.
   Web of Science ®Google Scholar
• Laugel B, van den Berg HA, Gostick E, Cole DK, Wooldridge L, Boulter J, Milicic A, Price DA, Sewell AK. Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties. J Biol Chem. 2007;282(33):23799–23810. doi:10.1074/jbc.M700976200.
   PubMed Web of Science ®Google Scholar
• Dolton G, Lissina A, Skowera A, Ladell K, Tungatt K, Jones E, Kronenberg-Versteeg D, Akpovwa H, Pentier JM, Holland CJ, et al. Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells: comparison of pMHC-I tetramers and dextramers. Clin Exp Immunol. 2014;177(1):47–63. doi:10.1111/cei.12339.
   PubMed Web of Science ®Google Scholar
• Hadrup SR, Bakker AH, Shu CJ, Andersen RS, van Veluw J, Hombrink P, Castermans E, Thor Straten P, Blank C, Haanen JB, et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods. 2009;6(7):520–526. doi:10.1038/nmeth.1345.
   PubMed Web of Science ®Google Scholar
• Newell EW, Sigal N, Bendall SC, Nolan GP, Davis MM. Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8 + T cell phenotypes. Immun. 2012;36(1):142–152. doi:10.1016/j.immuni.2012.01.002.
   Web of Science ®Google Scholar
• Zhang SQ, Ma KY, Schonnesen AA, Zhang M, He C, Sun E, Williams CM, Jia W, Jiang N. High-throughput determination of the antigen specificities of T cell receptors in single cells. Nat Biotechnol. 2018;36(12):1156–1159. doi:10.1038/nbt.4282.
   Web of Science ®Google Scholar
• Dolton G, Tungatt K, Lloyd A, Bianchi V, Theaker SM, Trimby A, Holland CJ, Donia M, Godkin AJ, Cole DK, et al. More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers. Immunology. 2015;146(1):11–22. doi:10.1111/imm.12499.
   PubMed Web of Science ®Google Scholar
• Rius C, Attaf M, Tungatt K, Bianchi V, Legut M, Bovay A, Donia M, Thor Straten P, Peakman M, Svane IM, et al. Peptide–MHC Class I tetramers can fail to detect relevant functional T cell clonotypes and underestimate antigen-reactive T cell populations. J Immunol. 2018;200(7):2263–2279. doi:10.4049/jimmunol.1700242.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD, Crystal JS, et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest. 2015;125(10):3981–3991. doi:10.1172/JCI82416.
   PubMed Web of Science ®Google Scholar
• Ren L, Leisegang M, Deng B, Matsuda T, Kiyotani K, Kato T, Harada M, Park JH, Saloura V, Seiwert T, et al. Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma. OncoImmunol. 2019;8(4):e1568813. doi:10.1080/2162402X.2019.1568813.
   PubMed Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Olsson N, Wagar LE, Fast E, Liu CL, Muftuoglu Y, Sworder BJ, Diehn M, Levy R, et al. Predicting HLA class II antigen presentation through integrated deep learning. Nat Biotechnol. 2019;37(11). doi:10.1038/s41587-019-0280-2.
   Web of Science ®Google Scholar
• Peng S, Zaretsky JM, Ng AHC, Chour W, Bethune MT, Choi J, Hsu A, Holman E, Ding X, Guo K, et al. Sensitive detection and analysis of neoantigen-specific t cell populations from tumors and blood. Cell Rep. 2019;28(10):2728–2738.e7. doi:10.1016/j.celrep.2019.07.106.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med. 1996;183(1):87–97. doi:10.1084/jem.183.1.87.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. PNAS. 2002;99(20):13009–13013. doi:10.1073/pnas.202491499.
   PubMed Web of Science ®Google Scholar
• Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res. 2001;61:3388–3393.
   PubMed Web of Science ®Google Scholar
• Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, Boczkowski D, Nair SK, Ballo MS, Gilboa E, et al. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol. 2001;166(5):2953–2960. doi:10.4049/jimmunol.166.5.2953.
   PubMed Web of Science ®Google Scholar
• Ali M, Foldvari Z, Giannakopoulou E, Böschen ML, Strønen E, Yang W, Toebes M, Schubert B, Kohlbacher O, Schumacher TN, et al. Induction of neoantigen-reactive T cells from healthy donors. Nat Protoc. 2019;14(6):1926–1943. doi:10.1038/s41596-019-0170-6.
   PubMed Web of Science ®Google Scholar
• Linnemann C, van Buuren MM, Bies L, Verdegaal EME, Schotte R, Calis JJA, Behjati S, Velds A, Hilkmann H, El Atmioui D, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med. 2014;21(1):81–85. doi:10.1038/nm.3773.
   PubMed Web of Science ®Google Scholar
• García-Guerrero E, Sánchez-Abarca LI, Domingo E, Ramos TL, Bejarano-García JA, Gonzalez-Campos JA, Caballero-Velázquez T, Pérez-Simón JA. Selection of tumor-specific cytotoxic T lymphocytes in acute myeloid leukemia patients through the identification of T-cells capable to establish stable interactions with the leukemic cells: “Doublet Technology”. Front Immunol. 2018;9:1971. doi:10.3389/fimmu.2018.01971.
   PubMed Web of Science ®Google Scholar
• Miyahira Y, Murata K, Rodriguez D, Rodriguez JR, Esteban M, Rodrigues MM, Zavala F. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods. 1995;181(1):45–54. doi:10.1016/0022-1759(94)00327-S.
   PubMed Web of Science ®Google Scholar
• Betts MR, Brenchley JM, Price DA, de Rosa SC, Douek DC, Roederer M, Koup RA. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281(1–2):65–78. doi:10.1016/s0022-1759(03)00265-5.
   PubMed Web of Science ®Google Scholar
• Lu YC, Zheng Z, Robbins PF, Tran E, Prickett TD, Gartner JJ, Li YF, Ray S, Franco Z, Bliskovsky V, et al. An efficient single-cell RNA-seq approach to identify neoantigen-specific T cell receptors. Mol Ther. 2018;26(2):379–389. doi:10.1016/j.ymthe.2017.10.018.
   PubMed Web of Science ®Google Scholar
• Klinger M, Kong K, Moorhead M, Weng L, Zheng J, Faham M. Combining next-generation sequencing and immune assays: a novel method for identification of antigen-specific T Cells. PLoS One. 2013;8(9):e74231. doi:10.1371/journal.pone.0074231.
   PubMed Web of Science ®Google Scholar
• Klinger M, Pepin F, Wilkins J, Asbury T, Wittkop T, Zheng J, Moorhead M, Faham M. Multiplex identification of antigen-specific T cell receptors using a combination of immune assays and immune receptor sequencing. PLoS One. 2015;10(10):e0141561. doi:10.1371/journal.pone.0141561.
   PubMed Web of Science ®Google Scholar
• Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009;27:591–619. doi:10.1146/annurev.immunol.021908.132706.
   PubMed Web of Science ®Google Scholar
• Jaigirdar A, Rosenberg SA, Parkhurst M. A high-avidity WT1-reactive T-cell receptor mediates recognition of peptide and processed antigen but not naturally occurring WT1-positive tumor cells. J Immunother. 2016;39(3):105–116. doi:10.1097/CJI.0000000000000116.
   PubMed Web of Science ®Google Scholar
• van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J, Taylor-Weiner A, Kester L, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161(4):933–945. doi:10.1016/j.cell.2015.03.053.
   PubMed Web of Science ®Google Scholar
• Dijkstra KK, Cattaneo CM, Weeber F, Clevers H, Schumacher TN, Voest Correspondence EE, Chalabi M, van de Haar J, Fanchi LF, Slagter M, et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell. 2018;174(1586–1598):e12. doi:10.1016/j.cell.2018.07.009.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299–308. doi:10.1038/nrc2355.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Sci. 2015;348(6230):69–74. doi:10.1126/science.aaa4971.
   PubMed Web of Science ®Google Scholar
• Effern M, Glodde N, Braun M, Liebing J, Boll HN, Yong M, Bawden E, Hinze D, van den Boorn-konijnenberg D, Daoud M, et al. Adoptive T cell therapy targeting different gene products reveals diverse and context-dependent immune evasion in melanoma. Immun. 2020. doi:10.1016/j.immuni.2020.07.007.
   Google Scholar
• Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, Rao A, Restifo NP, et al. Defining ‘T cell exhaustion. Nat Rev Immunol. 2019;19(11). doi:10.1038/s41577-019-0221-9.
   PubMed Web of Science ®Google Scholar
• de Simone M, Rossetti G, Pagani M. Single cell T cell receptor sequencing: techniques and future challenges. Front Immunol. 2018;9(Jul):1638. doi:10.3389/fimmu.2018.01638.
   PubMed Web of Science ®Google Scholar
• Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, Hiatt J, Saco J, Krystofinski P, Li H, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nat. 2018;559(7714):405–409. doi:10.1038/s41586-018-0326-5.
   Web of Science ®Google Scholar
• Schober K, Müller TR, Busch DH. Orthotopic T-cell receptor replacement-An “Enabler” for TCR-based therapies. Cells. 2020;9(6). doi:10.3390/cells9061367.
   Web of Science ®Google Scholar
• Allen BM, Hiam KJ, Burnett CE, Venida A, DeBarge R, Tenvooren I, Marquez DM, Cho NW, Carmi Y, Spitzer MH. Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. Nat Med. 2020;1–10. doi:10.1038/s41591-020-0892-6.
   PubMed Web of Science ®Google Scholar
• Karpanen T, Olweus J. The potential of donor T-cell repertoires in neoantigen-targeted cancer immunotherapy. Front Immunol. 2017;8(DEC):1718. doi:10.3389/fimmu.2017.01718.
   PubMed Web of Science ®Google Scholar
• O’Sullivan D, Pearce EL. Targeting T cell metabolism for therapy. Trends Immunol. 2015;36(2):71–80. doi:10.1016/j.it.2014.12.004.
   PubMed Web of Science ®Google Scholar
• Klein Geltink RI, Edwards-Hicks J, Apostolova P, O’Sullivan D, Sanin DE, Patterson AE, Puleston DJ, Ligthart NAM, Buescher JM, Grzes KM, et al. Metabolic conditioning of CD8+ effector T cells for adoptive cell therapy. Nat Metab. 2020;2(8). doi:10.1038/s42255-020-0256-z.
   PubMedGoogle Scholar
• Krishna S, Lowery FJ, Copeland AR, Bahadiroglu E, Mukherjee R, Jia L, Anibal JT, Sachs A, Adebola SO, Gurusamy D, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Sci. 2020;370(6522). doi:10.1126/science.abb9847.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell. 2020;183(2). doi:10.1016/j.cell.2020.08.053.
   PubMed Web of Science ®Google Scholar
• Butterfield LH. Cancer vaccines. BMJ (Online). 2015;350. doi:10.1136/bmj.h988.
   Google Scholar
• Sahin U, Derhovanessian E, Miller M, Kloke B-P, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nat. 2017;547(7662). doi:10.1038/nature23003.
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Marc GP, Moreira GD, Zerbini C. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine N Engl J Med. 2020. 383:2603–2615.
   Google Scholar
• Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372–385. doi:10.1038/s41571-019-0184-6.
   PubMed Web of Science ®Google Scholar
• Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M, Kroemer G, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immun. 2016;44(6):1255–1269. doi:10.1016/j.immuni.2016.06.001.
   Web of Science ®Google Scholar
• Walsh SR, Simovic B, Chen L, Bastin D, Nguyen A, Stephenson K, Mandur TS, Bramson JL, Lichty BD, Wan Y. Endogenous T cells prevent tumor immune escape following adoptive T cell therapy. J Clin Invest. 2019;129(12):5400–5410. doi:10.1172/JCI126199.
   PubMed Web of Science ®Google Scholar
• Lai J, Mardiana S, House IG, Sek K, Henderson MA, Giuffrida L, Chen AXY, Todd KL, Petley EV, Chan JD, et al. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat Immunol. 2020;1–13. doi:10.1038/s41590-020-0676-7.
   PubMed Web of Science ®Google Scholar
• Torrejon DY, Abril-Rodriguez G, Champhekar AS, Tsoi J, Campbell KM, Kalbasi A, Parisi G, Zaretsky JM, Garcia-Diaz A, Puig-Saus C, et al. Overcoming genetically-based resistance mechanisms to PD-1 blockade. Cancer Discov. 2020 May 28;CD–19–1409. doi:10.1158/2159-8290.cd-19-1409.
   PubMed Web of Science ®Google Scholar
• Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863–871. doi:10.1182/blood-2013-03-490565.
   PubMed Web of Science ®Google Scholar
• Wolf B, Zimmermann S, Arber C, Irving M, Trueb L, Coukos G. Safety and tolerability of adoptive cell therapy in cancer. Drug Saf. 2019;42(2). doi:10.1007/s40264-018-0779-3.
   PubMed Web of Science ®Google Scholar
• Etxeberria I, Olivera I, Bolaños E, Cirella A, Teijeira Á, Berraondo P, Melero I. Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms. Cell Mol Immunol. 2020;17(6):576–586. doi:10.1038/s41423-020-0464-1.
   PubMed Web of Science ®Google Scholar